Abstract
High dose melphalan remains the preparative regimen of choice for autologous hematopoietic stem cell transplantation (auto HCT) in multiple myeloma (MM). Bortezomib is an active agent in newly diagnosed or relapsed MM, and has synergistic activity with melphalan. We recently conducted two randomized phase II trials in MM, one of which studied the safety and efficacy of adding bortezomib to high-dose melphalan in the preparative regimen for auto HCT. Here we report the response rates, progression-free survival (PFS) and overall survival (OS) between the melphalan-based preparative regimens with or without bortezomib.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
